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SUPPLEMENTARY NOTES
ABSTRACT
Seladin-1 maps to the human chromosome region 1p31-1p32 that shows frequent loss of heterozygosity (LOH) in human breast tumors. Publicly available data (Entrez, GEO) also show a significant variability between levels of Seladin-1 expression in breast cancer cell lines and normal breast epithelium. Is Seladin-1 a tumor suppressor on 1p31-1p32 that is involved in breast cancer? Our concept is that it is. In order to determine if Seladin-1 is a TSG involved in breast cancer we propose to: 1) Identify possible Seladin-1 mutations in primary breast tumors. 2) Investigate the alterations of Seladin-1 expression in breast cancer cells. 3) Perform functional assays on tumor-specific Seladin-1 mutants. Accordingly, we amplified Seladin-1 exons from from 60 breast tumor genomic DNA samples (obtained from tissue banks or commercial sources), followed by the sequence analysis of the open reading frames. As a result, no missense or nonsense mutations were detected. We found that expression of Seladin-1 significantly varies between different breast cancer cell lines, and in one such line, MDA-MB-231, is significantly below expression in normal breast epithelium.
SUBJECT TERMS
breast cancer, breast cancer cell lines, Seladin-1 Seladin-1 has been described recently as a novel regulator of p53, a major human tumor suppressor gene (TSG; [1] ). Seladin-1 acts to counteract Mdm2 and promote accumulation of p53 in response to oncogenes and oxidative stress [1] . P53 is implicated in breast cancer progression, but it is mutated only in a fraction of human breast tumors [2] , suggesting that additional mechanisms might be involved in functional inactivation of the p53 checkpoint in tumors expressing wild type p53. Additionally, Seladin-1 (under DHCR24 alias) is also involved in cholesterol metabolism [3] . Cholesterol metabolism is known to be a contributing factor in cancer progression.
In order to determine if Seladin-1 is a TSG involved in breast cancer we propose to : Initially, we amplified the Seladin-1 exons from 60 breast tumor genomic DNA samples (all were obtained from a commercial source (Oncomatrix, Inc.), followed by the sequence analysis of the open reading frames. As a result, we did not we encounter finding mutations in the coding region and exon-intron junctions (other than known single nucleotide polymorphisms (SNPs).
However, we found high frequency (12-25%) new insertion/deletion polymorphism in the area close to exon7 (Fig.1) . We observed a single nucleotide deletion (IVS6: delT -29…-36) in a stretch of seven consequent T upstream of exon 7 of Seladin-1 (see Fig.1 ) in genomic DNA of patients with breast tumors. This type of sequence belongs to a structure commonly referred to as the polypyrimidine tract. The exact size of polypyrimidine tract is gene-specific, but it has been shown that a single nucleotide deletion in this tract results in exon skipping or abnormal splicing, sometimes causing nonsense-mediated mRNA decay and resulting in several different inherited diseases. The actual sequence analysis of one breast tumor sample with this polymorphism is shown in Fig. 2 . 
Reverse sequence delT
We analyzed whether the matching DNA from unaffected organs of the same patient. In case of this particular polymorphism, both tumor material and patients DNA obtained from unaffected tissues have the same polymorphism. We are now investigated whether this particular polymorphism is present with higher or lower frequency in breast cancer patient population comparing with unaffected individuals. No statistically significant differences were shown, therefore this polymorphism is unlikely to be important for the eventual development of breast cancer.
We submitted an abstract describing early stages of this research to Cold Spring Harbor Symposium on Quantitative Biology (see attached).
Our final analysis of this polymorphism was accepted to the Era of Hope Breast Cancer Conference (see attached).
Task2. Investigate alterations of Seladin-1 expression in breast cancer cells (months 1-12).
Accordingly, we isolated RNAs from human breast cell lines MCF7, BTK20, T47D, HBL100, MDA-MB-231, MDA-MB-468 and MCF10A. Total RNA isolation was done with Trizol (Invitrogen) as described by the manufacturer. Seladin-1 Probe labeling and hybridization was done as described previously using commercial kits. As a control, we used RNA from three different batches of normal mammary epithelial cells (HMEC). For immunoblotting, we used antibodies against C-terminal domain of Seladin-1, described in [1] .
When RNAs from 10 primary breast cancer cell lines were were analyzed, the conclusions on Seladin-1 gene expression was that this gene is usually expressed at high level in breast cancer cells (with the exception of MDA-MB-231). Interestingly, expression of Seladin-1 in MDA-MB-231 cell line was subjected to regulation by 5aza-2'-deoxycytidine (5AzadC), a demethylating agent. An increase in Seladin-1 expression in response to 5AzaDC indicates that this putative cell line was a candidate for promoter methylation studies using methylation-specific PCR and bisulfite sequencing. However, despite our best efforts, none of the primers designed to perform methylation studies had worked on promoter region of Seladin-1 (probably due to very high C/G content in those areas). More efforts in this regard are currently ongoing.
